Synonyms: 2-Amino-6-[[[2-(4-chlorophenyl)-1,3-thiazol-4-yl]methyl]sulfanyl]-4-[4-(2-hydroxyethoxy)phenyl]pyridine-3,5-dicarbonitrile; 2-Amino-6-[[[2-(4-chlorophenyl)-4-thiazolyl]methyl]thio]-4-[4-(2-hydroxyethoxy)phenyl]-3,5-pyridinedicarbonitrile; BAY 68-4986; BAY-68-4986; BAY68-4986
Molecular Formula: C25H18ClN5O2S2
Molecular Weight: 520.03
Linear Structural Formula: C25H18ClN5O2S2
MDL Number: MFCD09954113
Purity: >=98% (HPLC)
Storage: 2-8C
Biochem Physiol Actions: Capadenoson (BAY 68-4986) is an adenosine receptor A1 (A1AR) partial agonist (GTPgammaS binding EC50/Emax = 0.1 nM/74% vs. 0.3 nM/100% with CCPA; human cortex membranes) that exerts additional biased A2BAR agonism toward cAMP signal transduction (pEC50 = 8.94/cAMP, 6.20/Ca+2, 6.12/pERK, 5.03/IP1), while exhibiting weak A2A & A3 potency. Capadenoson offers cardioprotection efficacy in an ischemia-reperfusion injury rat model in vivo (25/28% infarct size reduction with 0.1/0.3 mg/kg iv.) without the risk of a full atrioventricular (AV) block (isolated perfused rat heart rate = 100% up to 10 nM, 90% at >=10 muM) seen with the full A1 agonist CCPA.